Mitsubishi UFJ Asset Management Co. Ltd. Has $59.84 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 144,011 shares of the company’s stock after acquiring an additional 11,056 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.18% of IDEXX Laboratories worth $59,841,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Cerity Partners LLC boosted its stake in shares of IDEXX Laboratories by 25.2% in the 3rd quarter. Cerity Partners LLC now owns 10,924 shares of the company’s stock valued at $5,519,000 after purchasing an additional 2,202 shares during the last quarter. Kingsview Wealth Management LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter worth $507,000. Centaurus Financial Inc. bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $115,000. FMR LLC lifted its stake in shares of IDEXX Laboratories by 3.6% in the 3rd quarter. FMR LLC now owns 290,861 shares of the company’s stock valued at $146,949,000 after purchasing an additional 10,017 shares during the period. Finally, D.A. Davidson & CO. boosted its position in shares of IDEXX Laboratories by 9.5% in the 3rd quarter. D.A. Davidson & CO. now owns 1,629 shares of the company’s stock worth $823,000 after purchasing an additional 142 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 1.6 %

Shares of NASDAQ:IDXX opened at $415.87 on Friday. The firm has a market cap of $33.71 billion, a price-to-earnings ratio of 38.98, a PEG ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88. The company’s fifty day simple moving average is $437.07 and its 200 day simple moving average is $443.27.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IDXX. Morgan Stanley dropped their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Leerink Partners started coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Finally, Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.